Singulair(R) In Asthma And Allergic Rhinitis (0476-383)

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Patient is a user of Inhaled Corticosteroid (ICS) or ICS/Long-Acting Beta 2-Agonist (ICS/LABA) at any dosage

• Peak expiratory flow is > or = 80% of predicted value on the day of visit 1

• Uncontrolled as per Canadian asthma consensus guidelines

Exclusion Criteria:

• Unwilling to stop regular use of histamine H1 antagonists for allergic rhinitis symptoms

• Unwilling to stop use of antihistamine eye drops or cromoglycate eye drops or ophthalmic corticosteroid